Huge market potential for CBD and other cannabinoids – how best to produce them?

January 25, 2021

While cannabis has been removed from the UN prohibition schedule and CBD is not considered as a narcotic drug, these two major decisions are expected to drive further research to explore the full potential of one of the major and longest established medicinal plants.

A new report “Production of Cannabinoids via Extraction, Chemical Synthesis and Especially Biotechnology – Current Technologies, Potential & Drawbacks and Future Development” provides all information on production technologies, medical applications and political framework conditions (http://www.renewable-carbon.eu/publications).

Huge market potential for CBD and other cannabinoids – how best to produce them?

Cannabis sativa as one of the oldest and most versatile cultivated plants has been used by humans for over 5,000 years, ranging from fibre production over seeds for food and feed, as well as oils for food and technical applications to medicinal use of cannabinoids for the treatment of pain, depression and nausea among a variety of other symptoms. After 60 years of being listed as a Schedule IV controlled substance, also referred to as the “prohibition schedule”, the UN has removed Cannabis and Cannabis resin from this list. In addition, natural CBD, first announced to might qualify as a narcotic under the UN Single Convention on Narcotic Drugs, has been declared to be not considered as such by the European Commission. These decisions will enable and drive further research to access the full medicinal potential. 

Cannabinoids are one of the best-known and extensively studied classes of secondary metabolites from C. sativa. For 40 years ∆9-THC is classified as a narcotic drug and authorised by the Food and Drug Administration (FDA) as a medicinal product for medical issues and uses, such as side effects of cancer chemotherapy and loss of appetite with weight loss in HIV/AIDS patients. On the other hand, the non-psychotropic CBD is assumed to currently account for 50 % of the global hemp industry revenue, expecting this CBD market to grow globally up to USD 3.5 billion in 2024. Besides these two commonly known cannabinoids, about 120 different cannabinoids have been identified in total in C. sativa.

Targeted biotechnological synthesis of the currently known 120 different cannabinoids that are only represented in small amounts in the plant can circumvent the current limits of unveiling the pharmacological profile and effects.

Biotechnological production routes and resulting synergistic effects with current state-of-the-art extraction and production processes will enable the elucidation of possible further beneficial effects of these molecules, that are currently unknown. Biotechnological production of cannabinoids can be achieved in many different ways: In eukaryotes, such as plants, algae, eukaryotic cell cultures and yeast, but also in prokaryotes, such as bacteria, or in enzymatic cell-free systems. Natural cannabinoid synthesis in C. sativa is performed via a complex pathway system that combines enzymes, products and intermediates from three different pathways.

The report is a guide through the complex synthesis of cannabinoids, state-of-the-art methods for extraction and production and will extensively show the major hidden potential and synergistic effects of biotechnological cannabinoid production. It is aimed at experts in the pharmaceutical and biotech industry and provides deep insights into (bio)chemical reactions, processes and producers.

The main authors are biotechnology experts and physicians from the nova-Institute, Dr. Pia Skoczinski and Dr. med. Franjo Grotenhermen, and the chemist Dr. rer. nat. Bernhard Beitzke, who has been advising the “European Industrial Hemp Association” (EIHA) as an expert for years. The 142-page technology report provides in-depth information on established and emerging biotechnological approaches on the production of cannabinoids, as well as an overview on the state-of-the-art production methods using plant extraction and chemical synthesis. An extensive description of pharmacological effects, therapeutic potential and medicinal applications for ∆9-tetrahydrocannabinol (∆9-THC) and cannabidiol (CBD), together with a short excursus on the EU regulatory framework for cannabinoids, conclude this comprehensive study. Additionally, 59 companies active in cannabinoid production are listed, from which 20 specialised in biotechnological production and chemical synthesis are described in detail.

What is the current status of plant extraction and chemical synthesis? What requirements are needed for biotechnological cannabinoid production? What is the most promising production host? What are the advantages and disadvantages of plant extraction, chemical synthesis and biotechnological cannabinoid production? Does biotechnology have the potential to provide rare cannabinoids in significant amounts? Which synergies might emerge with these three production routes and how can they drive the future development of cannabinoid production? 

The answers to these questions and the current state of biotechnological cannabinoid production, as well as plant extraction and chemical synthesis have been extensively reviewed and finally compared to show general technology-related claims and to elaborate the potential of biotechnological cannabinoid production, possible synergistic effects of all three production routes and to outline the future development of cannabinoid production.

Read: Medical marijuana: good evidence for some diseases, weak for others

Tags: , ,

Category: Features, Top Story

Comments are closed.

Subscribe to HCA for exclusive updates

Top Viewed News

12 simple steps to a healthy lifestyle

12 simple steps to a healthy lifestyle

Now that the world has returned to normalcy following the pandemic, everyone is back to their daily routines and encounters with stress... Read More

AZBIL: Envisioning the Future of Hospitals

AZBIL: Envisioning the Future of Hospitals

As we strive to be the hospital of choice, why not refine our commitment to excellence beyond the pivotal mission of saving lives?... Read More

Study Unlocks Key Findings on Asian Carriers of Breast Cancer

Study Unlocks Key Findings on Asian Carriers of Breast Cancer

Malaysian researchers at Cancer Research Malaysia (CRMY) and the University of Nottingham Malaysia (UNM) have published... Read More

 Unmasking the Risks of Mercury-Laden Cosmetics

Unmasking the Risks of Mercury-Laden Cosmetics

As the saying goes, beauty is in the eye of the beholder and thus subjective; but in some countries, the ideal of beauty begins... Read More

5 key hospital etiquettes to be mindful of when visiting a sick patient

5 key hospital etiquettes to be mindful of when visiting a sick patient

In moments of illness, the presence of loved ones can comfort and support. However, it’s important for visitors... Read More

Free counters!

2025 Exhibitions



2025 Events


8-11 May
Vietnam Medi-Pharm
MITEC, KL
www.vietnammedipharm.vn


21-22 May
HealthTechX Asia
Sands Expo & Convention Centre, Singapore
www.healthtechx-asia.com


5-7 June
Medical Taiwan
Taipei Nangang Exhibition Center, Taipei, Taiwan
www.medicaltaiwan.com.tw


9-11 June
APHM International Healthcare Conference & Exhibition
KL Convention Centere, Kuala Lumpur, Malaysia
www.aphmconferences.com


12-14 June
International Health Industry Expo
China
www.ihe-china.com


24-26 June
CPhI China
SNIEC, Shanghai, China
www.cphi.com


25-26 June
Health Facilities Asia
Singapore
www.www.iqpc.com


25-27 June
Japan Health
INTEX Osaka, Japan
www.japanhealthonline.com


26-27 June
OSH India South
Chennai Trade Center, Bangalore
www.oshindia.com


9-11 July
Medical Device Development (MEDIX) – Osaka
Makuhari Messe, Japan
www.manufacturing-world.jp


14-16 July
Lab Asia
Kuala Lumpur Convention Centre (KLCC), Malaysia
www.lab-asia.com


16-18 July
Medlab Asia | Asia Health
Malaysia International Trade & Exhibition Centre, Kuala Lumpur
www.medlabasia.com


13-15 August
Philippines Medical
SMX Convention Center Manila Philippines
www.philmedical.com


21-23 August
REHACARE China
Suzhou, China
www.rehacare-c.com


21-23 August
Medical Fair China
Suzhou, China
www.medicalfair.cn


3-5 September
Bio Asia Pacific
BITEC, Bangkok
www.bioasiapacific.com


9-12 September
China Dental Show
National Exhibition and Convention Center (Shanghai)
www.chinadentalshow.com


10-11 September
Hospital Management Asia
Shangri-La Kuala Lumpur, Malaysia
www.hospitalmanagementasia.com


10-12 September
Medical Fair Thailand
BITEC, Bangkok
www.medicalfair-thailand.com


10-12 September
Malaysia Pharma and Healthcare Expo
Kuala Lumpur, Malaysia
www.mphcexpo.com


11-13 September
Bio Asia Pacific
BITEC, Bangkok
www.bioasiapacific.com


24-26 September
Medtec China
Shanghai, China
www.en.medtecchina.com


9-11 October
Medical Japan Tokyo
Makuhari Messe, Japan
www.medical-jpn.jp


17-19 October
Health Asia
BITEC, Bangkok
www.health-asia.com


17-19 October
Health Asia
BITEC, Bangkok
www.health-asia.com


7-8 November
Eldercare Exhibition and Conference Asia (ELDEX Asia)
Suntex Singapore Exhibition and Convention Centre
www.eldexasia.com


10-12 November
Saudi International Pharma Expo
Riyadh International Convention and Exhibition Center
www.saudipharmaexpo.com


10-12 November
Saudi International MedLab Expo
Riyadh International Convention and Exhibition Center
www.saudimedlabexpo.com


27-29 November
International Wellness Expo (IWE 2025)
METIC, Malaysia
www.internationalwellnessexpo.com


2026 Events


9-12 Febuary
Arab Health
Dubai World Trade Centre
www.arabhealthonline.com


15-17 April
Lab Indonesia
Jakarta Convention Center, Jakarta, Indonesia
www.lab-indo.com


9-11 September
Medical Fair Asia
Marina Bay Sands, Singapore
www.medicalfair-asia.com


9-11 September
Medical Manufacturing Asia
Marina Bay Sands, Singapore
www.medmanufacturing-asia.com